Differences in rpoB, katG and inhA mutations between new and previously treated tuberculosis cases using the GenoType MTBDRplus assay

Differences in rpoB, katG and inhA mutations between new and previously treated tuberculosis... Drug resistance in new cases reflects primary transmission of resistant strains, while drug resistance in previously treated patients is more likely to reflect acquired resistance during previous tuberculosis (TB) treatment. In this study from a rural hospital in South India, we compared molecular differences between new and previously treated TB patients who had isoniazid or rifampicin resistance-conferring mutations using the GenoType MTBDRplus assay. Out of 2112 TB patients, 245 (11.6%) had rpoB mutations and 338 (16%) had isoniazid resistance-conferring mutations. Among patients with rpoB mutations, the proportion of new and previously treated cases with no isoniazid resistance-conferring mutations was 41.2% and 26% (P-value = 0.02; risk ratio [RR] 1.58, 95% confidence interval [CI] 1.09–2.31; risk difference [RD] 15.2%, 95% CI 18.2–28.6), respectively. Among patients with isoniazid resistance-conferring mutations, the proportion of new and previously treated cases with no rpoB mutations was 71.8% and 33.2% (P-value < 0.0001; RR 2.17, 95% CI 1.73–2.71; RD 38.7%, 95% CI 28.8–48.6), and the proportion with single inhA mutations (versus having katG mutations) was 33.1% and 20.9% (P-value = 0.012; RR 1.58, 95% CI 1.11–2.27; RD 12.2%, 95% CI 2.57–21.8), respectively. The most common resistance mutations were S531 L in the rpoB gene, S315T1 in the katG gene and C15T in the inhA gene, and there were no significant differences between new and previously treated patients. In conclusion, new TB cases were less likely to have combined isoniazid and rifampicin resistance-conferring mutations and, in cases with isoniazid resistance, they were more likely to have single inhA mutations than katG mutations. Taking into account that previous research has shown katG mutations precede mutations in the rpoB gene in most cases of rifampicin resistant TB, our results suggest a negative epistatic association between katG and rpoB mutations. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Infection, Genetics and Evolution Elsevier

Differences in rpoB, katG and inhA mutations between new and previously treated tuberculosis cases using the GenoType MTBDRplus assay

Loading next page...
 
/lp/elsevier/differences-in-rpob-katg-and-inha-mutations-between-new-and-previously-nR0A0GoXxT
Publisher
Elsevier
Copyright
Copyright © 2018 Elsevier B.V.
ISSN
1567-1348
D.O.I.
10.1016/j.meegid.2018.01.022
Publisher site
See Article on Publisher Site

Abstract

Drug resistance in new cases reflects primary transmission of resistant strains, while drug resistance in previously treated patients is more likely to reflect acquired resistance during previous tuberculosis (TB) treatment. In this study from a rural hospital in South India, we compared molecular differences between new and previously treated TB patients who had isoniazid or rifampicin resistance-conferring mutations using the GenoType MTBDRplus assay. Out of 2112 TB patients, 245 (11.6%) had rpoB mutations and 338 (16%) had isoniazid resistance-conferring mutations. Among patients with rpoB mutations, the proportion of new and previously treated cases with no isoniazid resistance-conferring mutations was 41.2% and 26% (P-value = 0.02; risk ratio [RR] 1.58, 95% confidence interval [CI] 1.09–2.31; risk difference [RD] 15.2%, 95% CI 18.2–28.6), respectively. Among patients with isoniazid resistance-conferring mutations, the proportion of new and previously treated cases with no rpoB mutations was 71.8% and 33.2% (P-value < 0.0001; RR 2.17, 95% CI 1.73–2.71; RD 38.7%, 95% CI 28.8–48.6), and the proportion with single inhA mutations (versus having katG mutations) was 33.1% and 20.9% (P-value = 0.012; RR 1.58, 95% CI 1.11–2.27; RD 12.2%, 95% CI 2.57–21.8), respectively. The most common resistance mutations were S531 L in the rpoB gene, S315T1 in the katG gene and C15T in the inhA gene, and there were no significant differences between new and previously treated patients. In conclusion, new TB cases were less likely to have combined isoniazid and rifampicin resistance-conferring mutations and, in cases with isoniazid resistance, they were more likely to have single inhA mutations than katG mutations. Taking into account that previous research has shown katG mutations precede mutations in the rpoB gene in most cases of rifampicin resistant TB, our results suggest a negative epistatic association between katG and rpoB mutations.

Journal

Infection, Genetics and EvolutionElsevier

Published: Apr 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off